Q3 FY2026 · ended Sep 30, 2026 · Revenue $1.56B, +14.0% YoY · Filed Oct 29, 2026
Incyte Corporation (INCY) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $1.6 billion and a net loss of $784.8 million. As of Sep 30, 2026 it held $3.3 billion in cash and investments and $37.4 million in total debt.
Revenue
$1.56B
+14.0% vs year-ago quarter
Net income
$-784.80M
-285.0% vs year-ago quarter
Operating cash flow
$-675.32M
-220.7% vs year-ago quarter
Free cash flow
—
EPS
$-3.86
-282.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
203.83M
+3.8% vs year-ago quarter
Net cash
$3.24B
Q3 FY2026
Operating margin
10.4%
TTM
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- INCY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Large accelerated filer
- SEC CIK
- 879169
- Former names
- INCYTE INC (until Mar 28, 2003); INCYTE GENOMICS INC (until Feb 25, 2003); INCYTE PHARMACEUTICALS INC (until Apr 18, 2000)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.6B | $1.7B | $1.3B | $1.5B | $1.4B |
| Operating income | -$708.4M | $697.9M | $301.1M | $335.9M | $443.5M |
| Net income | -$784.8M | $585.6M | $303.3M | $299.3M | $424.2M |
| Diluted EPS | -$3.86 | $2.81 | $1.47 | $1.46 | $2.11 |
| Operating cash flow | -$675.3M | $507.7M | $369.4M | $543.3M | $559.4M |
| Total assets | $7.3B | $7.9B | $7.3B | $7.0B | $6.3B |
| Total liabilities | $1.6B | $1.5B | $1.7B | $1.8B | $1.7B |
| Stockholders' equity | $5.6B | $6.3B | $5.6B | $5.2B | $4.7B |
| Cash and investments | $3.3B | $4.0B | $3.5B | $3.1B | $2.5B |
| Total debt | $37.4M | $38.3M | $39.4M | $54.9M | $41.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Aug 31, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Jul 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Other events
|
Jul 6, 2026 | Jul 6, 2026 |
All 1003 Incyte Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.